Sarepta rises on NZ regulatory nod to start Huntington's disease trial

Sarepta Therapeutics

04/02/2026 13:47

** Shares of  Sarepta Therapeutics SRPT.O 3% at $20.92 premarket

** Drugmaker says it received approval in New Zealand to begin first human study of SRP‑1005 for Huntington's disease, a rare fatal brain disorder

** Co's SRP‑1005 is an experimental treatment designed to target the genetic cause of the condition - SRPT

** Early‑stage trial to enroll about 24 participants and focus on safety and tolerability; study expected to start in Q2 2026, per co

** Huntington's disease is a rare inherited disorder that damages nerve cells in the brain, causing worsening movement and thinking problems

** Shares down ~82% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))